Sai Life Sciences doubles process R&D capacity with new facility in Hyderabad

Written by Emily J. Thompson, Senior Investment Analyst

Source: Businesswire

Updated: Oct 28 2025

0mins

Source: Businesswire

New Facility Announcement: Sai Life Sciences has laid the foundation for a new CMC Process R&D Center in Hyderabad, expected to be completed by September 2026, which will double the company's process R&D capacity.
Focus on Peptide Development: The new facility will enhance capabilities in peptide development, oligo-intermediates and linkers, formulation development, and clinical needs for early-phase projects.
CEO's Statement: Krishna Kanumuri, CEO, emphasized the need for speed, flexibility, and scientific depth in response to partners' demands, highlighting the center's role in improving efficiency in the development continuum.
Official Announcement: The announcement is made in the original language, with translations provided for reading assistance, but the original text is the only legally valid version.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free